Literature DB >> 1687338

Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse.

M J Akpaffiong1, P Ruiz.   

Abstract

One hundred and sixty psychiatric patients on Neuroleptics, with and without a history of substance abuse were daily monitored in order to establish the incidence of neuroleptic malignant syndrome in these two groups. Four (5.1%) of the cocaine abusers and none of the non-cocaine abusers developed neuroleptic malignant syndrome when treated with neuroleptics. Thus we argue that psychiatric patients with a history of cocaine abuse may be more at risk of developing neuroleptic malignant syndrome when treated with neuroleptics, possibly associated with the blockade of dopamine (D2-receptors) by neuroleptics and the activation of dopamine/5-HT receptors by cocaine-induced dopamine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687338     DOI: 10.1007/bf01958798

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  22 in total

1.  Neurochemical effects of cocaine following acute and repeated injection.

Authors:  D Taylor; B T Ho
Journal:  J Neurosci Res       Date:  1977       Impact factor: 4.164

Review 2.  Neuroleptic malignant syndrome.

Authors:  R Kurlan; R Hamill; I Shoulson
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592

3.  Neuroleptic malignant syndrome.

Authors:  S Weinberg; R S Twersky
Journal:  Anesth Analg       Date:  1983-09       Impact factor: 5.108

4.  Frequency and presentation of neuroleptic malignant syndrome: a prospective study.

Authors:  P E Keck; H G Pope; S L McElroy
Journal:  Am J Psychiatry       Date:  1987-10       Impact factor: 18.112

5.  Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'.

Authors:  D F Levinson; G M Simpson
Journal:  Arch Gen Psychiatry       Date:  1986-09

6.  Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Authors:  J M Cleghorn; R D Kaplan; B Szechtman; H Szechtman; G M Brown; S Franco
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

7.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.

Authors:  R E Burke; S Fahn; R Mayeux; H Weinberg; K Louis; J H Willner
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

9.  Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.

Authors:  T Y Lew; G Tollefson
Journal:  Biol Psychiatry       Date:  1983-12       Impact factor: 13.382

Review 10.  The neuroleptic malignant syndrome: agent and host interaction.

Authors:  A Shalev; H Munitz
Journal:  Acta Psychiatr Scand       Date:  1986-04       Impact factor: 6.392

View more
  2 in total

1.  Excited delirium: Consideration of selected medical and psychiatric issues.

Authors:  Edith Samuel; Robert B Williams; Richard B Ferrell
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

2.  Neuroleptic malignant syndrome in the trauma intensive care unit: Diagnosis and management of a rare disease in a challenging population.

Authors:  Joseph David Drews; Andrew Christopher; David Clay Evans
Journal:  Int J Crit Illn Inj Sci       Date:  2017 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.